Novel Therapies in Hepatic Encephalopathy.

Maryam Alimirah, Omar Sadiq, Stuart C Gordon

Journal: Clinics in liver disease 2021;24(2):303-315

PMID: 32245535

Full Text on Elsevier Science View on PubMed

Abstract

Despite widespread use of lactulose and rifaximin for the treatment of hepatic encephalopathy, this complication of advanced liver disease remains a major burden on the health care system in the United States and continues to predispose to high morbidity and mortality. Several agents have surfaced over recent years with promise to treat hepatic encephalopathy and mitigate the cognitive impairment associated with this disease process. The purpose of this article is to highlight the leading emerging therapies in hepatic encephalopathy as well as their therapeutic targets.

Address: Department of Internal Medicine, Henry Ford Hospital, 2799 West Grand Boulevard, CFP-1, Detroit, MI 48202, USA.; Department of Gastroenterology and Hepatology, Henry Ford Hospital, 2799 West Grand Boulevard, K7, Detroit, MI 48202, USA.; Department of Gastroenterology and Hepatology, Henry Ford Hospital, 2799 West Grand Boulevard, K7, Detroit, MI 48202, USA; Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: [email protected].

DOI: 10.1016/j.cld.2020.01.009

Link outs

Subscription / membership required

Full Text Sources:

MeSH Terms: Acetylcarnitine, Albumins, Ammonia, Dipeptides, Fecal Microbiota Transplantation, Flumazenil, GABA Modulators, Glycerol, Hepatic Encephalopathy, Humans, Nootropic Agents, Ornithine, Phenylbutyrates, Polyethylene Glycols, Probiotics, Surface-Active Agents